UBS O'Connor
ONCE

UBS O'Connor’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

UBS O'Connor’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-20,000
Closed -$1.02M – 528
2016
Q2 		$1.02M Sell
20,000
-106,033
-84% -$4.53M 0.02% 300
2016
Q1 		$3.72M Sell
126,033
-67,967
-35% -$2.14M 0.04% 282
2015
Q4 		$8.79M Buy
+194,000
New +$10.2M 0.08% 205

Other funds holding ONCE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $33.4B AUM 56.97% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 20.64% 1-Year Est. Return

UBS O'Connor's ONCE Position: Q3 2016 in Review

UBS O'Connor sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q3 2016, closing a stake of 20,000 shares — an estimated $1.02M sold.

UBS O'Connor first reported a position in ONCE in Q4 2015 and held it in 3 quarters. The position peaked at $8.79M in Q4 2015. 121 funds tracked by Wall St. Rank hold ONCE as of Q3 2016.

  • UBS O'Connor reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q3 2016 after selling out during the quarter.
  • UBS O'Connor sold 20,000 Spark Therapeutics, Inc. Common Stock shares in Q3 2016, an estimated $1.02M.
  • UBS O'Connor first reported a position in Spark Therapeutics, Inc. Common Stock in Q4 2015 and held it in 3 quarters.
  • UBS O'Connor's Spark Therapeutics, Inc. Common Stock position peaked at $8.79M in Q4 2015.
  • 121 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q3 2016.

Based on UBS O'Connor's 13F filing for Q3 2016, filed 14 Nov 2016.